Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Century Therapeutics

Main focus: Next-generation cell therapies for the treatment of cancer

Company stage: Pre-clinical

Diseases (gene editing): Cancer

Genome editing tool: CRISPR-MAD7

Funding stage: Public (NASDAQ:IPSC)

Location: Philadelphia, PA, USA



Gene-editing partnerships: Inscripta, Bristol Myers Squibb

Century Therapeutics is developing next-generation cell-based therapies to treat haematological and solid tumours. The company uses its iPSC platform to generate allogeneic, iPSC-derived natural killer (NK) and T cell products. The company uses the CRISPR-MAD7 system to introduce multiple knock-outs to its cellular products, in order to avoid host-versus-graft reactions and increase persistence and durability.


HashtagCentury Therapeutics

Company: Century Therapeutics
Search CRISPR Medicine